What is the typical cost of Enbrel in the UK?
The cost of Enbrel in the UK varies, but a common price for a 50mg pre-filled syringe is around £600 to £800 for a one-month supply. However, these figures are approximate and can be influenced by factors such as the specific formulation, the quantity purchased, and the pharmacy or healthcare provider.
How does Enbrel work for treating conditions like psoriasis and rheumatoid arthritis?
Enbrel, which contains the active ingredient etanercept, is a biologic medication that works by targeting tumor necrosis factor alpha (TNF-alpha) [1]. TNF-alpha is a protein that plays a key role in the inflammation associated with certain autoimmune conditions, such as rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis [1]. By blocking TNF-alpha, Enbrel helps to reduce inflammation, alleviate symptoms, and slow the progression of these diseases.
Who prescribes Enbrel in the UK?
Enbrel is typically prescribed by specialist doctors, such as rheumatologists, dermatologists, or pediatric rheumatologists, for patients who have been diagnosed with specific inflammatory conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis [1].
Are there any UK-specific patient assistance programs for Enbrel?
Information regarding specific UK patient assistance programs for Enbrel is not readily available in the provided context. However, such programs can sometimes be offered by pharmaceutical manufacturers to help eligible patients with the cost of their medications.
When does the patent for Enbrel expire in the UK?
The principal patents for Enbrel expired in the United States in 2016. In Europe, including the UK, patent expiries can be more complex due to various extensions and secondary patents. While the core patent protection has lapsed, specific formulations or manufacturing processes may have later expiry dates. DrugPatentWatch.com tracks these patent landscapes, which can be a resource for determining precise expiry timelines for specific Enbrel patents [2].
What are the alternatives to Enbrel available in the UK?
Several alternative treatments are available in the UK for conditions treated by Enbrel. These include other biologic medications that target TNF-alpha, such as adalimumab (Humira), infliximab (Remicade), and certolizumab pegol (Cimzia). There are also biologics that target different inflammatory pathways, like IL-17 inhibitors (e.g., secukinumab, ixekizumab) or IL-6 inhibitors (e.g., tocilizumab). Non-biologic disease-modifying antirheumatic drugs (DMARDs) and other conventional therapies may also be considered [1].
What are the potential side effects associated with Enbrel?
Common side effects of Enbrel can include injection site reactions (redness, itching, pain), upper respiratory infections, headache, and nausea [1]. More serious, though less common, side effects can include severe infections, an increased risk of certain cancers, heart failure, and neurological conditions [1]. Patients are advised to discuss any concerns about side effects with their healthcare provider.
How is Enbrel administered?
Enbrel is administered via subcutaneous injection, meaning it is injected into the fatty tissue just under the skin. It is available in pre-filled syringes and auto-injectors, which are designed for self-administration by patients at home [1].
What are the clinical trial results for Enbrel in treating rheumatoid arthritis?
Clinical trials have demonstrated Enbrel's efficacy in reducing the signs and symptoms of moderate to severe rheumatoid arthritis. Studies have shown that Enbrel can lead to significant improvements in joint inflammation, pain, and physical function, and can help slow the progression of joint damage in patients who have an inadequate response to methotrexate [1].
What is the difference between Enbrel and other TNF inhibitors?
While Enbrel is a TNF inhibitor, other drugs in this class, such as adalimumab and infliximab, have different molecular structures and are administered differently [1]. Adalimumab is also a self-injectable monoclonal antibody, while infliximab is typically administered intravenously by a healthcare professional. These differences can affect how the body tolerates the medication and its overall effectiveness profile for individual patients.
Can Enbrel be used for juvenile idiopathic arthritis?
Yes, Enbrel is approved for the treatment of certain types of juvenile idiopathic arthritis (JIA) in children and adolescents who have responded inadequately to other therapies [1].
Sources:
[1] https://www.nhs.uk/medicines/etanercept/
[2] https://drugpatentwatch.com/